AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01585441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule with no active ingredients to mimic finasteride
Trial: NCT02231229
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
Trial: NCT03211728
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
Trial: NCT03854019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
Trial: NCT00847821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
Trial: NCT03416413
Drug: Foam sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of foam sclerosant into varicose vein tributaries
Trial: NCT03792321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04563299
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive a sham dilation.
Trial: NCT04563299
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All eyes (n=40) will receive anti-VEGF injections for the treatment of AMD, DME and macular edema secondary to RVO. Twenty eyes (one eye per patient) will be randomized to receive Dextenza. The contra-lateral eye (Control) will receive topical corticosteroids (prednisolone acetate 1%) QID tapered over 4 weeks (QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week).
Trial: NCT01640171
Drug: Proparacaine Hydrochloride 0.5% Drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical drop given first to the treated eye.
Trial: NCT02444728
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 1000mg intravenous infusion every month for 6 months
Trial: NCT02444728
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
Trial: NCT00665223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules will be swallowed whole with water.
Trial: NCT00338949
Drug: Switch
RxNorm normalized name: Universal Footswitch Covers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
Trial: NCT04539067
Drug: HHMG
RxNorm normalized name: Hydroxymethylglutaryl-CoA Reductase Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG
Trial: NCT01976364
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 7.5-20 mg weekly
Trial: NCT01976364
Drug: Placebo Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match active methotrexate orally once a week
Trial: NCT02196077
Drug: BFF MDI 320/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Trial: NCT02196077
Drug: BFF MDI 160/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Trial: NCT02196077
Drug: BFF MDI 80/9.6 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Trial: NCT01613963
Drug: Immunosuppressive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
Trial: NCT02698306
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac Sodium
Trial: NCT01619657
Drug: 6% Hypertonic Saline (HS), 4mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
Trial: NCT01619657
Drug: 0.9% Isotonic Saline (IS), 4mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
Trial: NCT02040987
Drug: AZD3293
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3293 oral solution - one single dose (low dose).
Trial: NCT02040987
Drug: AZD3293
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3293 oral solution - one single dose (high dose).
Trial: NCT02040987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral solution - one single dose
Trial: NCT02612506
Drug: Hepalatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
Trial: NCT02612506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
Trial: NCT01266161
Drug: Ibuprofen 600 mg ER
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One 600 mg caplet dosed at 0, 12, 24 and 36 hours
Trial: NCT01266161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo caplet dosed at times 0, 12, 24 and 36 hours
Trial: NCT04092452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00612222
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
Trial: NCT00602186
Drug: tamsolusin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg /day
Trial: NCT02831179
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02888379
Drug: TOP1288
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02888379
Drug: Placebo (for TOP1288)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02313337
Drug: Anesthesia induction(midazolam,fentanyl,propofol,atracurium)
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
Trial: NCT02313337
Drug: Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
Trial: NCT01267240
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00889967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily by inhalation for 28 days
Trial: NCT01560195
Drug: Pegylated rhG-CSF: 100µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve\[AUC\] 5 or cisplatin 75 mg/m2.
Trial: NCT00115336
Drug: Intravenous Ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac
Trial: NCT00115336
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen, taken orally
Trial: NCT03096756
Drug: GC4702 dry powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg
Trial: NCT03096756
Drug: GC4702 lipid suspension
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg
Trial: NCT01965106
Drug: QPI-1007 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg QPI-1007 Injection
Trial: NCT00095043
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002498
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002498
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002498
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002498
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01243060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time dose of Placebo
Trial: NCT02415920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
Trial: NCT01536210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
Trial: NCT00367913
Drug: Addition of clarithromycin to rifampicin and ethambutol
RxNorm normalized name: rifampicin, ethambutol and isoniazid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03880695
Drug: Anlotinib+ Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks
Trial: NCT00172081
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injection with placebo
Trial: NCT00172081
Drug: ALX1-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
Trial: NCT04192513
Drug: J. lividum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product
Trial: NCT01760018
Drug: TIVA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anesthesia is maintained with fresofol and remifentanil (TIVA group).
Trial: NCT00885326
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
Trial: NCT02999711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00885326
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
Trial: NCT02014883
Drug: GLUT1 DS
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03229616
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Trial: NCT00569803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
Trial: NCT01316341
Drug: BI10773
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
Trial: NCT01316341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient to receive two placebos
Trial: NCT01316341
Drug: BI10773
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
Trial: NCT01058083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Oral, 0 mg, daily, 28 days
Trial: NCT00708305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride free toothpaste (0ppmF)
Trial: NCT03491748
Drug: ETX0282
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Gelatin capsules
Trial: NCT03491748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Gelatin capsules
Trial: NCT03180879
Drug: Test - RB ibuprofen acid orodispersible tablets
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
Trial: NCT03180879
Drug: Reference - RB Nurofen ibuprofen acid tablets
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
Trial: NCT03512197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.
Trial: NCT03512197
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.
Trial: NCT03180879
Drug: Comparator - Dolormin ibuprofen lysine tablets
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
Trial: NCT00723424
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, for 13 days
Trial: NCT01466790
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC435 will be administered as one oral capsule of 150 mg once a day.
Trial: NCT00002740
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002740
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02923193
Drug: Medtronic IN.PACT (DCB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
Trial: NCT03514381
Drug: Patients starting a treatment with Doxorubicin and Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 9 blood samples will be collected at each Cycle:~* Cycle 1 (Day 1-Day 2-Day 3)~* Cycle 2 (Day 1-Day 2-Day 3)
Trial: NCT03438240
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Plus 50 µg fentanyl
Trial: NCT02419729
Drug: Placebo of Estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of topical estrogen cream.
Trial: NCT00926575
Drug: oral beclomethasone 17,21-dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets QID for 50 days
Trial: NCT00926575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets QID for 50 days
Trial: NCT01027364
Drug: rFIX
RxNorm normalized name: rFIXFc
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01381835
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg capsule once daily for 7 days
Trial: NCT01939301
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric Oxide + oxygen
Trial: NCT01939301
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen + Oxygen
Trial: NCT02762838
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive methotrexate in a dose from 10 to 25 mg per week.
Trial: NCT02762838
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive folic acid in a dose of 5 mg per week.
Trial: NCT00811421
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
Trial: NCT01258660
Drug: EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
Trial: NCT01258660
Drug: EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yasmin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)\] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
Trial: NCT00495092
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
Trial: NCT03653663
Drug: Simvastatin 20 mg
RxNorm normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are treated with 20 mg simvastatin for 8 weeks
Trial: NCT03653663
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are treated with placebo for 8 weeks
Trial: NCT01812538
Drug: DIC075V
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four single dose treatments:~* Placebo (normal saline)~* Moxifloxacin (positive control)~* DIC075V 37.5 mg~* DIC075V 75 mg~All subjects receive each of the 4 treatments.
Trial: NCT04205929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
Trial: NCT01586338
Drug: Hylan G-F 20
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection (pre-filled glass syringe)
Trial: NCT00089895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous; delivery to match eptifibatide to maintain blind